Ultragenyx sells priority review voucher for $210 million, retains another to monetize
read at Endpoints ↗DealPositive
Ultragenyx Pharmaceutical announced it has sold a priority review voucher to an undisclosed buyer for $210 million.
The transaction is among the highest-priced voucher sales this year, providing a significant cash infusion for the company.
Ultragenyx also indicated it retains another priority review voucher, which it plans to monetize in the future.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Ultragenyx sells PRV for $210M and still has another to monetize”
read at Endpoints ↗81 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that